Q1 EPS Forecast for Axsome Therapeutics Lowered by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at William Blair decreased their Q1 2025 EPS estimates for Axsome Therapeutics in a research note issued to investors on Tuesday, February 18th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($1.46) for the quarter, down from their previous estimate of ($0.95). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.74) per share. William Blair also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($4.23) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $13.85 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Several other equities research analysts also recently weighed in on AXSM. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price target for the company. Truist Financial raised their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners lifted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. Finally, Wells Fargo & Company lifted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $158.79.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $137.75 on Friday. The company has a market capitalization of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05. The company has a quick ratio of 2.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm has a 50 day moving average of $101.29 and a 200 day moving average of $94.91. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Pitcairn Co. lifted its stake in shares of Axsome Therapeutics by 3.4% during the 4th quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock valued at $386,000 after buying an additional 148 shares in the last quarter. Meridian Wealth Management LLC lifted its stake in shares of Axsome Therapeutics by 0.7% during the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock valued at $1,791,000 after buying an additional 150 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Axsome Therapeutics by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company’s stock valued at $326,000 after buying an additional 162 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Axsome Therapeutics by 1.8% during the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock valued at $766,000 after buying an additional 164 shares in the last quarter. Finally, Intrust Bank NA lifted its stake in shares of Axsome Therapeutics by 6.9% during the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock valued at $239,000 after buying an additional 183 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.